Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: A meta-analysis

Parkinsonism and Related Disorders

Volumn 18, Issue 6, 2012, Pages 722-730

  Wu, Xi ^a,b   Tang, Ke Fu ^a,b   Li, Yang ^a,b   Xiong, Yu Yu ^a,b   Shen, Lu ^a,b   Wei, Zhi Yun ^a,b   Zhou, Ke Jun ^a,b   Niu, Jia Min ^c   Han, Xia ^c   Yang, Lun ^a,b   Feng, Guo Yin ^a,b   He, Lin ^a,b,d   Qin, Sheng Ying ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c Laiwu Hospital   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

LRRK2; Meta analysis; PARK8; Parkinson's disease (PD); Variant

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

CASE CONTROL STUDY; ETHNICITY; EXON; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEUCINE RICH REPEAT KINASE 2 GENE; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW;

EXONS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84862210838     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2012.04.013     Document Type: Review

References (76)

1. Fahn S. Description of Parkinson's disease as a clinical syndrome. Annals of the New York Academy of Sciences. 2003, 991:1-14.
2. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
3. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
4. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. New England Journal of Medicine 2006, 354:422-423.
5. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine 2006, 354:424-425.
6. Ross O.A., Wu Y.R., Lee M.C., Funayama M., Chen M.L., Soto A.I., et al. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Annals in Neurology 2008, 64:88-92.
7. Di Fonzo A., Wu-Chou Y.H., Lu C.S., van Doeselaar M., Simons E.J., Rohe C.F., et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006, 7:133-138.
8. Wu T., Zeng Y., Ding X., Li X., Li W., Dong H., et al. A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. Neuroreport 2006, 17:1859-1862.
9. Ross O.A., Soto-Ortolaza A.I., Heckman M.G., Aasly J.O., Abahuni N., Annesi G., et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurology 2011, 10:898-908.
10. DerSimonian R., Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary Clinical Trials 2007, 28:105-114.
11. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959, 22:719-748.
12. Woolf B. On estimating the relation between blood group and disease. Annals in Human Genetics 1955, 19:251-253.
13. Papapetropoulos S., Singer C., Ross O.A., Toft M., Johnson J.L., Farrer M.J., et al. Clinical heterogeneity of the LRRK2 G2019S mutation. Archives of Neurology-Chicago 2006, 63:1242-1246.
14. Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J., Hulihan M., White L.R., et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Annals in Neurology 2005, 57:762-765.
15. Aguiar P.D.C., Lessa P.S., Godeiro C., Barsottini O., Felicio A.C., Borges V., et al. Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients. Movement Disorders 2008, 23:1228-1233.
16. Belin A.C., Westerlund M., Sydow O., Lundstromer K., Hakansson A., Nissbrandt H., et al. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Movement Disorders 2006, 21:1731-1734.
17. Berg D., Schweitzer K.J., Leitner P., Zimprich A., Lichtner P., Belcredi P., et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 2005, 128:3000-3011.
18. Bras J.M., Guerreiro R.J., Ribeiro M.H., Januario C., Morgadinho A., Oliveira C.R., et al. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Movement Disorders 2005, 20:1653-1655.
19. Clark L.N., Wang Y., Karlins E., Saito L., Mejia-Santana H., Harris J., et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006, 67:1786-1791.
20. Cossu G., van Doeselaar M., Deriu M., Melis M., Molari A., Di Fonzo A., et al. LRRK2 mutations and Parkinson's disease in Sardinia - a Mediterranean genetic isolate. Parkinsonism & Related Disorders 2007, 13:17-21.
21. Deng H., Le W.D., Guo Y., Hunter C.B., Xie W.J., Huang M.S., et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. Journal of Neurological Sciences 2006, 251:102-106.
22. Deng H., Le W.D., Guo Y., Hunter C.B., Xie W.J., Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Annals of Neurology 2005, 57:933-934.
23. Farrer M., Stone J., Mata I.F., Lincoln S., Kachergus J., Hulihan M., et al. LRRK2 mutations in Parkinson disease. Neurology 2005, 65:738-740.
24. Floris G., Cannas A., Solla P., Murru M.R., Tranquilli S., Corongiu D., et al. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: Importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients. Parkinsonism & Related Disorders 2009, 15:277-280.
25. Gao L., Gomez-Garre P., Diaz-Corrales F.J., Carrillo F., Carballo M., Palomino A., et al. Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain. Europen Journal of Neurology 2009, 16:957-960.
26. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005, 365:415-416.
27. Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M., et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late-onset Parkinson's disease and originates from a common ancestor. Journal of Medical Genetics 2005, 42.
28. Gonzalez-Fernandez M.C., Lezcano E., Ross O.A., Gomez-Esteban J.C., Gomez-Busto F., Velasco F., et al. Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism & Related Disorders 2007, 13:509-515.
29. Gorostidi A., Ruiz-Martinez J., de Munain A.L., Alzualde A., Masso J.F.M. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009, 10:157-159.
30. Hernandez D., Paisan Ruiz C., Crawley A., Malkani R., Werner J., Gwinn-Hardy K., et al. The Dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neuroscience Letters 2005, 389:137-139.
31. Hulihan M.M., Ishihara-Paul L., Kochergus J., Warren L., Amouri R., Elango R., et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. The Lancet Neurology 2008, 7:591-594.
32. Infante J., Rodriguez E., Combarros O., Mateo I., Fontalba A., Pascual J., et al. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neuroscience Letters 2006, 395:224-226.
33. Jasinska-Myga B., Kachergus J., Vilarino-Guell C., Wider C., Soto-Ortolaza A.I., Kefi M., et al. Comprehensive sequencing of the LRRK2 gene in patients with familial Parkinson's disease from North Africa. Movement Disorders 2010, 25:2052-2058.
34. Johnson J., Paisan-Ruiz C., Lopez G., Crews C., Britton A., Malkani R., et al. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegenerative Disorders 2007, 4:386-391.
35. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. American Journal on Human Genetics 2005, 76:672-680.
36. Kay D.M., Zabetian C.P., Factor S.A., Nutt J.G., Samii A., Griffith A., et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Movement Disorders 2006, 21:519-523.
37. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
38. Latourelle J.C., Sun M., Lew M.F., Suchowersky O., Klein C., Golbe L.I., et al. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Medicine 2008, 6:32.
39. Lesage S., Condroyer C., Lannuzel A., Lohmann E., Troiano A., Tison F., et al. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease. Journal of Medical Genetics 2009, 46:458-464.
40. Mata I.F., Ross O.A., Kachergus J., Huerta C., Ribacoba R., Moris G., et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. European Journal of Neurology 2006, 13:391-394.
41. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 2005, 365:410-412.
42. Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Human Mutation 2008, 29:485-490.
43. Patra B., Parsian A.J., Racette B.A., Zhao J.H., Perlmutter J.S., Parsian A. LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease. Parkinsonism & Related Disorders 2009, 15:175-180.
44. Pchelina S.N., Yakimovskii A.F., Ivanova O.N., Emelianov A.K., Zakharchuk A.H., Schwarzman A.L. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia. Movement Disorders 2006, 21:2234-2236.
45. Pulkes T., Papsing C., Mahasirimongkol S., Busabaratana M., Kulkantrakorn K., Tiamkao S. Frequencies of LRRK2 variants in Thai patients with Parkinson's disease: evidence for an R1628P founder. The Journal of Neurology, Neurosurgery, and Psychiatry 2011, 82:1179-1180.
46. Punia S., Behari M., Govindappa S.T., Swaminath P.V., Jayaram S., Goyal V., et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neuroscience Letters 2006, 409:83-88.
47. Xiromerisiou G., Hadjigeorgiou G.M., Gourbali V., Johnson J., Papakonstantinou I., Papadimitriou A., et al. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. European Journal of Neurology 2007, 14:7-11.
48. Yescas P., Lopez M., Monroy N., Boll M.C., Rodriguez-Violante M., Rodriguez U., et al. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Neuroscience Letters 2010, 485:79-82.
49. Zabetian C.P., Morino H., Ujike H., Yamamoto M., Oda M., Maruyama H., et al. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 2006, 67:697-699.
50. An X.K., Peng R., Li T., Burgunder J.M., Wu Y., Chen W.J., et al. LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. European Journal of Neurology 2008, 15:301-305.
51. Choi J.M., Woo M.S., Ma H.I., Kang S.Y., Sung Y.H., Yong S.W., et al. Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 2008, 9:263-269.
52. Farrer M.J., Stone J.T., Lin C.H., Dachsel J.C., Hulihan M.M., Haugarvoll K., et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism & Related Disorders 2007, 13:89-92.
53. Funayama M., Li Y.Z., Tomiyama H., Yoshino H., Imamichi Y., Yamamoto M., et al. Leucine-rich repeat kinase 2 G238SR variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007, 18:273-275.
54. Fung H.C., Chen C.M., Hardy J., Singleton A.B., Wu Y.R. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurology 2006, 6.
55. Kim J.M., Lee J.Y., Kim H.J., Kim J.S., Shin E.S., Cho J.H., et al. The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. Parkinsonism & Related Disorders 2010, 16:85-88.
56. Lu C.S., Wu-Chou Y.H., van Doeselaar M., Simons E.J., Chang H.C., Breedveld G.J., et al. The LRRK2 Arg1628Pro variant is a risk factor for Parkinson's disease in the Chinese population. Neurogenetics 2008, 9:271-276.
57. Miyake Y., Tsuboi Y., Koyanagi M., Fujimoto T., Shirasawa S., Kiyohara C., et al. LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: a case-control study in Japan. Journal of Neurological Science 2010, 297:15-18.
58. Nuytemans K., Meeus B., Crosiers D., Brouwers N., Goossens D., Engelborghs S., et al. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Human Mutations 2009, 30:1054-1061.
59. Tan E.K., Lim H.Q., Yuen Y., Zhao Y. Pathogenicity of LRRK2 P755L variant in Parkinson's disease. Movement Disorders 2008, 23:734-736.
60. Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L., et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Human Genetics 2007, 120:857-863.
61. Tan E.K., Zhao Y., Tan L., Lim H.Q., Lee J., Yuen Y., et al. Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians. Movement Disorders 2007, 22:1816-1818.
62. Tomiyama H., Mizuta I., Li Y., Funayama M., Yoshino H., Li L., et al. LRRK2 P755L variant in sporadic Parkinson's disease. Journal of Human Genetics 2008, 53:1012-1015.
63. Yao L.Y., Guo J.F., Wang L., Yu R.H., Sun Q.Y., Pan Q., et al. LRRK2 Pro755Leu variant in ethnic Chinese population with Parkinson's disease. Neurosci Letters 2011, 495:35-38.
64. Zabetian C.P., Yamamoto M., Lopez A.N., Ujike H., Mata I.F., Izumi Y., et al. LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Movement Disorders 2009, 24:1034-1041.
65. Zhang Z.J., Burgunder J.M., An X.K., Wu Y., Chen W.J., Zhang J.H., et al. LRRK2 R1628P variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China. Movement Disorders 2009, 24:1902-1905.
66. Li C., Ting Z., Qin X., Ying W., Li B., Qiang L.G., et al. The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson's disease. Movement Disord 2007, 22:2439-2443.
67. Yu L., Hu F., Zou X., Jiang Y., Liu Y., He X., et al. LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China. Brain Research 2009, 1296:113-116.
68. de Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
69. Tan E.K., Peng R., Teo Y.Y., Tan L.C., Angeles D., Ho P., et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Human Mutations 2010, 31:561-568.
70. Skipper L., Li Y., Bonnard C., Pavanni R., Yih Y., Chua E., et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Human Molecular Genetics 2005, 14:3549-3556.
71. Mata I.F., Kachergus J.M., Taylor J.P., Lincoln S., Aasly J., Lynch T., et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005, 6:171-177.
72. Goldwurm S., Zini M., Mariani L., Tesei S., Miceli R., Sironi F., et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007, 68:1141-1143.
73. Kay D.M., Kramer P., Higgins D., Zabetian C.P., Payami H. Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Movement Disorders 2005, 20:1077-1078.
74. Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F., Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006, 63:377-382.
75. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neuroscience 2006, 29:286-293.
76. Liu J., Zhou Y., Wang C., Wang T., Zheng Z., Chan P. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Parkinsonism & Related Disorders 2011.